Novo Nordisk (NVO) stock fell after announcing that CEO Lars Fruergaard Jørgensen will step down. BMO Capital Markets ...

Here's a recap of the week’s most important stories.

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Novo Nordisk (NVO) stock in focus as the company promotes FDA-approved Wegovy as a ban for makers of compounding versions ...

His replacement has not yet been found. Novo Nordisk stock is down 50% in 12 months, but priced cheaply and growing at nearly 20%. Investors may get a second bite at the apple, and a second chance ...

By Patrick Wingrove and Maggie Fick (Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply ...

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

The pharmaceutical giant Novo Nordisk announced on Friday, May 16, 2025, that CEO Lars Fruergaard Jørgensen is stepping down amid mounting challenges for the obesity drug maker. The sudden leadership ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, ...